How Saffron Works: Mechanisms of Action

How Saffron Works: Mechanisms of Action

1. Executive Mechanism Summary

Saffron (Crocus sativus L.) is the dried stigma of a purple crocus flower. Its biological activity is usually attributed to a small family of apocarotenoids, namely crocins, crocetin, safranal and picrocrocin, together with flavonoids such as kaempferol [1,2]. Instead of acting on a single receptor the way many drugs do, these molecules appear to nudge several biological systems at the same time.

The mechanistic themes that recur most often in the literature are:

•       Monoamine signaling: weak inhibition of serotonin, dopamine and norepinephrine reuptake in laboratory preparations [4,5].

•       Glutamate and GABA balance: reduced excitatory glutamatergic transmission, with possible GABAergic involvement [6,7,8].

•       Antioxidant defence: activation of the Nrf2 pathway and reduced lipid peroxidation [2,14].

•       Anti-inflammatory signaling: suppression of NF-κB-driven production of cytokines and nitric oxide [2,15].

•       Neuroplasticity and metabolism: support for BDNF/CREB signaling and for AMPK and insulin-related pathways [10,16].

It is important to be clear about the strength of the evidence. Almost all of these mechanisms were identified in cell cultures and animal models, often at concentrations or doses higher than what a person gets from a typical supplement. Human trials of saffron extract, mostly small and short, report benefits for mood, premenstrual symptoms and some other outcomes, but they do not show which mechanism produces those effects. This article explains each proposed pathway, shows where the evidence is strongest, and states plainly where it is not.

2. Key Active Compounds

Saffron is chemically complex, with more than 150 volatile and aroma-yielding compounds reported, but a handful of constituents account for most of the research interest [1].

Crocins and crocetin

Crocins are water-soluble esters formed between crocetin, a 20-carbon polyene dicarboxylic acid, and sugars such as glucose and gentiobiose. They give saffron its deep red-orange colour. Crocetin is the lipid-soluble backbone left when those sugars are removed.

This distinction matters for how saffron works in the body. In mice, orally administered crocins are hydrolysed in the gut, and what circulates in plasma is mainly crocetin and its glucuronide conjugates rather than intact crocin [3]. Many laboratory experiments apply crocin directly to cells, so their results may reflect crocetin more than crocin once the ingredient has been eaten. Crocetin is also the more lipophilic of the two, and animal studies suggest it may be better placed to reach the brain [2].

Safranal and picrocrocin

Picrocrocin is the bitter glycoside that gives saffron its taste. During drying and storage it breaks down into safranal, a small volatile molecule responsible for much of the characteristic aroma [1]. Because safranal is small and lipophilic, it crosses membranes easily, which is one reason it features prominently in studies of anxiety, sleep and seizure models [8,9].

Flavonoids and other constituents

Saffron stigmas also contain kaempferol derivatives, other flavonoids, carotenoids such as lycopene and zeaxanthin, and small amounts of vitamins. Saffron petals, a by-product of harvesting, are richer in flavonoids and anthocyanins and have been studied separately [2].

Composition is not constant. Growing region, harvest timing, drying method and storage all change the ratio of crocins to safranal, and saffron is among the spices most often adulterated. For that reason, a result seen with one standardised extract cannot automatically be applied to a different product.

3. Primary Biological Targets

Researchers describe saffron's "targets" in different ways. Some come from binding assays, where a compound physically attaches to a protein. Others come from functional readouts, such as a change in gene expression or enzyme activity after treatment. The list below mixes both kinds.

•       Neurotransmitter transporters: the serotonin, dopamine and norepinephrine transporters (SERT, DAT, NET), where saffron constituents showed reuptake inhibition in rodent brain preparations [4,5].

•       Ion-channel receptors: the NMDA receptor (including the phencyclidine site) and the sigma-1 receptor in binding studies [6], plus a proposed influence on GABA-A receptors [8,9].

•       Enzymes: acetylcholinesterase, inhibited in vitro and in docking models [11], and inflammatory enzymes such as COX-2 and iNOS, whose expression is reduced in treated cells [2,15].

•       Transcription factors: Nrf2 (antioxidant response), NF-κB (inflammation) and CREB (neuroplasticity) [2,10,14].

•       Kinase networks: MAPK (ERK, JNK, p38), PI3K/Akt and AMPK [2,16].

•       Protein aggregation: amyloid-beta fibril formation, which crocins inhibited in test-tube experiments [12].

•       Mitochondria and cell-death machinery: Bcl-2 family proteins and caspases [2,18].

One caution applies to nearly every item above. The affinities reported are usually in the micromolar range, much weaker than those of purpose-built drugs. Saffron probably works through small, cumulative effects across several targets and not through strong blockade of any single one.

4. Pathway 1: Serotonergic and Monoaminergic Modulation

Mood-related research is where saffron has the most human data, so it is no surprise that the monoamine system is the most studied pathway. Serotonin, dopamine and norepinephrine are released into the synapse and then cleared by dedicated transporters. Blocking those transporters lengthens the time the neurotransmitter spends in the synapse, which is the basic principle behind SSRIs and related antidepressants.

In rodent synaptosome preparations, constituents of saffron, including crocin and safranal, inhibited reuptake of all three monoamines, and different constituents appeared to favour different transporters [4,5]. In behavioural tests such as the forced swim and tail suspension tests, fractions of saffron extract reduced immobility, a result usually read as antidepressant-like [5]. Reviewers have therefore proposed a mild, SSRI-like contribution to the mood effects seen in clinical trials [4].

There are good reasons to be careful with that interpretation. The measured inhibition is far weaker than that of fluoxetine or other standard drugs, and the concentrations used in synaptosome experiments are not necessarily reached in human brain tissue after a 30 mg daily dose. Behavioural improvement in a mouse also does not prove transporter inhibition was the cause. A more cautious reading is that monoamine reuptake is one plausible contributor, working alongside the glutamatergic, neurotrophic and anti-inflammatory mechanisms described below.

5. Pathway 2: Glutamate (NMDA) and GABA Signaling

Glutamate is the brain's main excitatory neurotransmitter, and the NMDA receptor is one of its principal targets. Overactivation of NMDA receptors leads to excessive calcium entry, oxidative damage and neuronal injury, a process known as excitotoxicity. Disturbed glutamate signaling has been linked to depression, anxiety and neurodegenerative disease, which makes this pathway relevant to several of saffron's reported effects.

In binding experiments, saffron extract and some of its constituents showed affinity for the phencyclidine site of the NMDA receptor and for the sigma-1 receptor, although the affinities were modest [6]. In rat brain slices, saffron extract and trans-crocetin reduced glutamatergic synaptic transmission in the cortico-striatal pathway [7]. Together these findings suggest a mild dampening of excitatory signaling, comparable in kind to, but not in strength with, NMDA-targeting drugs.

GABAergic influence

Safranal and crocin produced anxiolytic and sedative-like effects in mice in a study of saffron constituents [8], and a later review proposed that GABAergic mechanisms may be involved alongside glutamate and monoamine effects [9]. Direct receptor-binding proof for GABA-A modulation is limited, so this should be treated as a hypothesis. If both mechanisms are real, a shift in the balance between excitation and inhibition could help explain the calming effects reported in animal models.

6. Pathway 3 and Beyond: Additional Mechanisms

Pathway 3: Neurotrophic signaling (BDNF and CREB)

Brain-derived neurotrophic factor (BDNF) supports neuronal survival, synaptic plasticity and the long-term response to antidepressant treatment. It is regulated by the transcription factor CREB. In a rat study, saffron aqueous extract produced antidepressant-like behaviour and changed CREB, BDNF and VGF expression in the hippocampus [10]. This fits a model in which saffron improves plasticity-related signaling in addition to altering neurotransmitter levels, but human evidence of the same effect, for example through blood BDNF or imaging studies, remains scarce.

Pathway 4: Cholinergic activity and protein aggregation

Alzheimer's disease involves cholinergic loss, amyloid-beta plaques and tau tangles. In docking and enzyme assays, saffron extract and its constituents inhibited acetylcholinesterase, the enzyme that breaks down acetylcholine, offering a possible reason for small cognitive benefits [11]. Crocins also reduced amyloid-beta aggregation in test-tube experiments [12]. These are early, indirect findings. They show that the compounds can interact with these targets in vitro, not that they alter plaque or tangle burden in the human brain.

Pathway 5: Retinal photoprotection

The retina is rich in polyunsaturated fats and exposed to light and oxygen, which makes it vulnerable to oxidative damage. In rats exposed to damaging light, saffron supplementation preserved photoreceptor structure and function [13]. Suggested explanations include antioxidant and anti-apoptotic actions inside photoreceptors, although the precise molecular steps are not settled. A small human study in early age-related macular degeneration reported improved retinal flicker sensitivity [25], which is encouraging but preliminary.

7. Cellular Signaling

PI3K/Akt and cell survival. Activation of Akt promotes survival by inhibiting pro-apoptotic proteins and glycogen synthase kinase-3. Crocin and crocetin have been reported to increase Akt phosphorylation in several preclinical models, which is consistent with reduced cell death after stress [2].

MAPK cascades. The MAPK family includes ERK, usually linked to plasticity and survival, and JNK and p38, which are activated by stress and inflammation. A pattern reported in several preclinical models is lower JNK and p38 activation alongside supported ERK signaling [2].

AMPK and energy sensing. AMPK acts as a cellular fuel gauge. Its activation increases glucose uptake and fat oxidation. In muscle cells, saffron extract increased glucose uptake through several pathways, including AMPK and insulin signaling [16].

Mitochondria and apoptosis. Crocin and crocetin have been shown to preserve mitochondrial membrane potential, raise the ratio of anti-apoptotic Bcl-2 to pro-apoptotic Bax, and lower caspase-3 activity in stressed cells [2,14].

Context-dependent effects. The same compounds can protect normal cells and promote cell death in tumour cell lines [18]. This apparent contradiction is common among polyphenols and carotenoids. Cancer cells often carry a different redox state and survival signaling profile, so a compound that supports stress resistance in a healthy neuron may tip a malignant cell toward apoptosis. These cell-line findings do not show that saffron treats cancer in people.

8. Oxidative Stress Pathways

Oxidative stress, an imbalance between reactive oxygen species and antioxidant defences, contributes to neurodegeneration, vascular disease, diabetes complications and ageing. Saffron appears to act on it in two ways.

Direct radical scavenging

Crocetin and crocins contain long chains of conjugated double bonds, which can neutralise free radicals in chemical assays, as other carotenoids do [1]. Safranal and kaempferol derivatives add further scavenging capacity. However, direct scavenging in a test tube is a weak predictor of effects in the body, because circulating concentrations after oral dosing are low and quickly conjugated [3].

Induction of endogenous defences

A more plausible route is indirect. Nrf2 is a transcription factor that, when released from its inhibitor Keap1, moves into the nucleus and switches on genes for heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase, superoxide dismutase, catalase and glutathione synthesis. Several preclinical studies report that crocin or crocetin raise Nrf2 activity and these downstream enzymes while lowering malondialdehyde, a marker of lipid peroxidation [2,14]. In endothelial cells exposed to oxidative challenge, saffron and its components reduced oxidative damage and apoptosis [14].

This indirect mechanism could explain why modest exposure produces measurable effects: a small signal that upregulates the cell's own antioxidant enzymes can have a larger and longer-lasting impact than direct scavenging. Human trials have measured antioxidant biomarkers with inconsistent results, so the translation to people is still open.

9. Inflammatory Pathways

Chronic low-grade inflammation is implicated in depression, neurodegeneration, metabolic disease and cardiovascular risk, so anti-inflammatory activity is relevant across saffron's proposed uses.

The central player is NF-κB, a transcription factor that is normally held inactive in the cytoplasm. Inflammatory stimuli such as lipopolysaccharide trigger degradation of its inhibitor, allowing NF-κB to enter the nucleus and drive expression of TNF-α, IL-1β, IL-6, COX-2 and inducible nitric oxide synthase. In rat microglial cells, crocin and crocetin reduced lipopolysaccharide-induced production of nitric oxide and pro-inflammatory mediators [15]. Other preclinical studies describe lower NF-κB activation and reduced TLR4 signaling after crocin treatment [2].

Microglia matter here because they are the brain's resident immune cells. Overactive microglia release cytokines and reactive oxygen species that injure neurons and may alter neurotransmitter metabolism. Calming them could connect saffron's anti-inflammatory effects to its neuroprotective and mood-related effects, although this link remains a hypothesis.

Small human trials have reported reductions in some inflammatory markers after saffron, yet the results differ between studies and populations, and no single marker has emerged as a reliable indicator of response.

10. Endocrine, Neurotransmitter and Metabolic Pathways

Stress axis and mood-related hormones

Chronic stress overactivates the hypothalamic-pituitary-adrenal (HPA) axis, raising cortisol (corticosterone in rodents) and impairing hippocampal plasticity. In some stress models, saffron or its constituents reduced stress-induced corticosterone elevation and behavioural changes [2,4]. This is plausible given the combined effects on serotonin, glutamate and BDNF, all of which interact with the HPA axis. In premenstrual syndrome, a randomised trial found symptom improvement with saffron [22]; the mechanism could involve serotonergic modulation of mood during hormonal change, but no study has shown that saffron alters sex hormone levels directly.

Appetite and satiety

In a placebo-controlled study of mildly overweight women, a saffron extract reduced snacking and increased satiety [17]. One proposed explanation is serotonin-related regulation of mood and appetite, which is reasonable but unproven.

Glucose and lipid metabolism

In cultured muscle cells, saffron extract increased glucose uptake and improved insulin sensitivity through several pathways, including AMPK and insulin-signaling components [16]. Animal studies describe lower blood glucose, improved insulin sensitivity and favourable lipid changes in diabetic and high-fat-fed rodents, often alongside reduced oxidative stress and inflammation in liver and fat tissue [2]. Because inflammation and oxidative stress themselves worsen insulin resistance, the metabolic effects may partly be secondary to the pathways described earlier. Human meta-analyses of metabolic markers report modest and heterogeneous effects, so metabolic benefits should be treated as possible and not established.

11. Mechanism Diagram

The diagram below summarises the main proposed routes from saffron's compounds to biological outcomes. The groupings are simplified, because in reality the compounds act on several targets at once and the pathways overlap.

Figure 1. Simplified map of proposed saffron mechanisms.

The same map is repeated below in text form.

Compound	Proposed target	Signaling effect	Biological outcome
Crocins / crocetin	Nrf2, NF-κB, MAPK, PI3K/Akt, AMPK	Higher antioxidant enzymes; lower cytokine output	Reduced oxidative and inflammatory stress; improved insulin signaling
Safranal	SERT, DAT, NET; NMDA; GABA-A (proposed)	Slower monoamine clearance; lower glutamate signaling	Mood, anxiety and sleep-related effects
Extract constituents	Acetylcholinesterase, amyloid-beta, CREB/BDNF	Altered cholinergic and plasticity signaling	Possible neuroprotection and cognitive support
Flavonoids (kaempferol)	Redox and inflammatory kinases	Radical scavenging; reduced NF-κB activity	Supportive antioxidant and anti-inflammatory activity

 

12. Preclinical Evidence

Cell culture. Experiments use neuronal lines, primary neurons, microglia, endothelial cells, muscle cells and many cancer cell lines. They are useful for identifying signaling effects, such as Nrf2 activation or NF-κB suppression, and for isolating individual compounds [2,14,15]. Their weakness is exposure: cells are often treated with micromolar concentrations of intact crocin, whereas the blood of an animal or person that ingests saffron contains mostly crocetin and its conjugates at lower levels [3].

Animal behaviour models. Rodent studies include the forced swim and tail suspension tests for depression-like behaviour, the elevated plus maze for anxiety, sleep and seizure models, and memory tasks after chemical impairment. Saffron extract, crocin and safranal improved performance in many of these [5,8,9]. Because these tests are indirect proxies, they cannot show that the same mechanism operates in human mood disorders.

Disease models. Saffron constituents have shown protective effects in models of ischaemia-reperfusion injury, diabetes, retinal light damage and amyloid toxicity [2,12,13]. The results are broadly consistent with the antioxidant, anti-inflammatory and anti-apoptotic mechanisms described above.

Common limitations. Animal doses are often tens of milligrams per kilogram of body weight, whereas clinical trials usually use about 30 mg of extract a day, which is well under 1 mg per kilogram. Many studies inject the compound, bypassing the gut hydrolysis that changes crocin into crocetin. Sample sizes are small, study methods vary, and most work comes from a limited number of research groups. Positive findings are therefore best seen as hypothesis-generating.

13. Human Relevance

Human research is where the mechanisms are tested against real-world outcomes, but it does so only indirectly.

Mood and anxiety

A meta-analysis of randomised trials in major depression reported that saffron was associated with a large improvement relative to placebo and with an effect comparable to standard antidepressants over short treatment periods [19]. An early pilot trial found that 30 mg of saffron extract daily performed similarly to fluoxetine over six weeks in mild to moderate depression [20]. In adolescents with mild anxiety and depressive symptoms, a standardised saffron extract improved scores compared with placebo [21]. The trials are mostly small and short, many were conducted by a few groups, and large independent replications are still needed.

Premenstrual symptoms and appetite

In a placebo-controlled trial, 30 mg of saffron daily for two menstrual cycles reduced premenstrual symptom scores [22]. The satiety study mentioned earlier reported less snacking in mildly overweight women [17].

Cognition and vision

In mild to moderate Alzheimer's disease, saffron improved cognitive scores relative to placebo over 16 weeks [24], and another trial reported results comparable to donepezil over 22 weeks [23]. Both were small. In early macular degeneration, saffron improved retinal flicker sensitivity in a small trial [25].

Safety and practical points

Short-term trials at around 20 to 30 mg of extract per day generally report good tolerability, though very large amounts are toxic and high intakes are avoided in pregnancy [26]. Because saffron may influence serotonin signaling and mood, people with bipolar disorder, or those taking antidepressants or other psychoactive medication, should speak with a clinician before supplementing.

What this means for the mechanisms

A symptom improvement in a trial is consistent with the proposed mechanisms but does not prove them. To link mechanism to outcome, researchers would need biomarker data, such as inflammatory markers, BDNF levels or neuroimaging, collected alongside clinical measures. Few saffron trials include such measures.

14. Mechanistic Uncertainty

The mechanisms above are best described as plausible and partly supported, not proven. The main gaps are:

•       Exposure and bioavailability. It is uncertain which circulating forms reach target tissues, at what concentrations, and for how long. Crocetin and its glucuronides are the main circulating forms in animals [3], yet most mechanistic work tests crocin or whole extract.

•       Weak affinities. Reported binding and reuptake effects are modest. Whether they are enough to change neurotransmission at supplement doses has not been demonstrated.

•       Compound attribution. Whole extracts contain many constituents, and it is often unclear whether an effect comes from crocin, crocetin, safranal, flavonoids or an interaction among them.

•       Product variability. Differences in saffron grade, processing and adulteration make results hard to compare across studies [1].

•       Study quality. Many clinical trials are small, short and from a small number of groups, with a possible risk of publication bias.

•       Species and route differences. Rodent metabolism, dose and route of administration differ from human oral supplementation.

•       Mechanism versus outcome. Almost no human study measures a mechanistic biomarker, so the pathways described here remain proposed.

•       Dual effects. Pro-survival effects in normal cells and pro-apoptotic effects in tumour cells show that activity depends on context, which complicates predictions [18].

Priorities for future research include pharmacokinetic studies in humans, trials with standardised and well-characterised extracts, head-to-head comparison of single compounds with whole extracts, and trials that pair clinical outcomes with biomarker measures. Until then, the most accurate summary is that saffron likely acts through several modest, overlapping mechanisms, and that its human effects are promising but not yet fully explained.

This article is for educational purposes and is not medical advice. Speak to a qualified healthcare professional before using saffron supplements, especially if you are pregnant, have a medical condition or take prescription medication.

15. References

[1]  Melnyk JP, Wang S, Marcone MF. Chemical and biological properties of the world's most expensive spice: saffron. Food Res Int. 2010;43(8):1981-1989.

[2]  Bukhari SI, Manzoor M, Dhar MK. A comprehensive review of the pharmacological potential of Crocus sativus and its bioactive apocarotenoids. Biomed Pharmacother. 2018;98:733-745.

[3]  Asai A, Nakano T, Takahashi M, Nagao A. Orally administered crocetin and crocins are absorbed into blood plasma as crocetin and its glucuronide conjugates in mice. J Agric Food Chem. 2005;53(18):7302-7306.

[4]  Lopresti AL, Drummond PD. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Hum Psychopharmacol. 2014;29(6):517-527.

[5]  Wang Y, Han T, Zhu Y, et al. Antidepressant properties of bioactive fractions from the extract of Crocus sativus L. J Nat Med. 2010;64(1):24-30.

[6]  Lechtenberg M, Schepmann D, Niehues M, Hellenbrand N, Wünsch B, Hensel A. Quality and functionality of saffron: quality control, species assortment and affinity of extract and isolated saffron compounds to NMDA and σ1 (sigma-1) receptors. Planta Med. 2008;74(7):764-772.

[7]  Berger F, Hensel A, Nieber K. Saffron extract and trans-crocetin inhibit glutamatergic synaptic transmission in rat cortico-striatal brain slices. Pharmazie. 2011;66(5):337-344.

[8]  Hosseinzadeh H, Noraei NB. Anxiolytic and hypnotic effect of Crocus sativus aqueous extract and its constituents, crocin and safranal, in mice. Phytother Res. 2009;23(6):768-774.

[9]  Pitsikas N. Constituents of saffron (Crocus sativus L.) as potential candidates for the treatment of anxiety disorders and schizophrenia. Molecules. 2016;21(3):303.

[10]  Ghasemi T, Abnous K, Vahdati F, et al. Antidepressant effect of Crocus sativus aqueous extract and its effect on CREB, BDNF, and VGF transcript and protein levels in rat hippocampus. Drug Res. 2015;65(7):337-343.

[11]  Geromichalos GD, Lamari FN, Papandreou MA, et al. Saffron as a source of novel acetylcholinesterase inhibitors: molecular docking and in vitro enzymatic studies. J Agric Food Chem. 2012;60(24):6131-6138.

[12]  Papandreou MA, Kanakis CD, Polissiou MG, et al. Inhibitory activity on amyloid-β aggregation and antioxidant properties of Crocus sativus stigmas extract and its crocin constituents. J Agric Food Chem. 2006;54(23):8762-8768.

[13]  Maccarone R, Di Marco S, Bisti S. Saffron supplement maintains morphology and function after exposure to damaging light in mammalian retina. Invest Ophthalmol Vis Sci. 2008;49(3):1254-1261.

[14]  Rahiman N, Akaberi M, Sahebkar A, Emami SA, Tayarani-Najaran Z. Protective effects of saffron and its active components against oxidative stress and apoptosis in endothelial cells. Microvasc Res. 2018;118:82-89.

[15]  Nam KN, Park YM, Jung HJ, et al. Anti-inflammatory effects of crocin and crocetin in rat brain microglial cells. Eur J Pharmacol. 2010;648(1-3):110-116.

[16]  Kang C, Lee H, Jung ES, et al. Saffron (Crocus sativus L.) increases glucose uptake and insulin sensitivity in muscle cells via multipathway mechanisms. Food Chem. 2012;135(4):2350-2358.

[17]  Gout B, Bourges C, Paineau-Dubreuil S. Satiereal, a Crocus sativus L extract, reduces snacking and increases satiety in a randomized placebo-controlled study of mildly overweight, healthy women. Nutr Res. 2010;30(5):305-313.

[18]  Abdullaev FI. Cancer chemopreventive and tumoricidal properties of saffron (Crocus sativus L.). Exp Biol Med. 2002;227(1):20-25.

[19]  Hausenblas HA, Saha D, Dubyak PJ, Anton SD. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. J Integr Med. 2013;11(6):377-383.

[20]  Noorbala AA, Akhondzadeh S, Tamacebi-Pour N, Jamshidi AH. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. J Ethnopharmacol. 2005;97(2):281-284.

[21]  Lopresti AL, Drummond PD, Inarejos-García AM, Prodanov M. affron®, a standardised extract from saffron (Crocus sativus L.) for the treatment of youth anxiety and depressive symptoms: a randomised, double-blind, placebo-controlled study. J Affect Disord. 2018;232:349-357.

[22]  Agha-Hosseini M, Kashani L, Aleyaseen A, et al. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG. 2008;115(4):515-519.

[23]  Akhondzadeh S, Shafiee Sabet M, Harirchian MH, et al. A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease. Psychopharmacology. 2010;207(4):637-643.

[24]  Akhondzadeh S, Sabet MS, Harirchian MH, et al. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. J Clin Pharm Ther. 2010;35(5):581-588.

[25]  Falsini B, Piccardi M, Minnella A, et al. Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010;51(12):6118-6124.

[26]  Moshiri M, Vahabzadeh M, Hosseinzadeh H. Clinical applications of saffron (Crocus sativus) and its constituents: a review. Drug Res. 2015;65(6):287-295.